General
Preferred name
S-3APG
Synonyms
POMALIDOMIDE ()
CC-4047 ()
Pomalidomide (CC-4047) ()
Pomalyst ()
4-NH2-Thal(Pomalidomide) ()
1c(poma) ()
3(poma) ()
PomalidomideA34764-Amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione ()
IMID3 ()
Pomalidomide accord ()
IMID 3 ()
Pomalidomide viatris ()
Imnovid (previously pomalidomide celgene) ()
Pomalidomide krka ()
Pomalidomida ()
Pomalidomide zentiva ()
Actimid ()
Imnovid ()
IMID-3 ()
Pomalidomide-d5 ()
P&D ID
PD004117
CAS
19171-19-8
1377838-49-7
Tags
available
molecular glue
drug
PROTAC
Approved by
PMDA
FDA
First approval
2013
Drug indication
myeloproliferative disorder
Systemic sclerosis
Drug Status
approved
investigational
experimental
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Pomalidomide is an analogue of thalidomide with similar immunomodulatory antineoplastic activity. (GtoPdb)
ABSORPTION Pomalidomide is generally well absorbed. The major circulating component is the parent compound. ; Tmax, single oral dose = 2 -3 hours. ; When 4 mg of promalidomide is given to patients with multiple myeloma, the steady-state pharmacokinetic parameters are as follows:; AUC(T) = 400 ng.hr/mL;; Cmax = 75 ng/mL. ; Promalidomide accumulates following multiple doses.
HALF-LIFE Healthy subjects = 9.4 hours;; Multiple myeloma patients = 7.5 hours.
DESCRIPTION Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.
DESCRIPTION Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. It is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib. (Enamine Bioactive Compounds)
DESCRIPTION Cereblon binder; induces ubiquitination and degradation of CK1alpha by E3 ubiquitin ligase (Tocris Bioactive Compound Library)
DESCRIPTION Pomalidomide (CC-4047) is an anti-angiogenic and immunomodulatory agent. Pomalidomide is a ligand for the ubiquitin E3 ligase cereblon (CRBN) and is commonly used in the synthesis of PROTAC products. (TargetMol Bioactive Compound Library)
Cell lines
7
Organisms
1
Compound Sets
26
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
JUMP-MOA Compound Set
MedChem Express Bioactive Compound Library
MolGlueDB
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
NIH Approved Oncology Drugs
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
External IDs
307
Properties
(calculated by RDKit )
Molecular Weight
273.07
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
2
Rotatable Bonds
1
Ring Count
3
Aromatic Ring Count
1
cLogP
-0.33
TPSA
109.57
Fraction CSP3
0.23
Chiral centers
1.0
Largest ring
6.0
QED
0.54
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
Apoptosis
Ligand for E3 Ligase
Molecular Glues
TNF-α
TNFa inhibitor
Apoptosis related,E3 Ligase ,E3 ligase Ligand,TNF-alpha
IKZF Family
Ligands for E3 Ligase
Primary Target
Ubiquitin E3 Ligases
MOA
TNF
Inhibitor
tumor necrosis factor production inhibitor
Therapeutic Indication
Anticancer
Pathway
Immunology/Inflammation
PROTAC
Source data